References: Melanoma Skin Cancer

American Academy of Pediatrics. Policy statement – Ultraviolet radiation: A hazard to children and adolescents. Pediatrics. 2011;127:588-597.

American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society; 2016.

American Cancer Society. Cancer Facts & Figures 2017. Atlanta, Ga: American Cancer Society; 2017.

American Joint Committee on Cancer. Melanoma of the skin. In: AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:325-344.

Berman B, Villa AM. Immune response modulators in the treatment of skin cancer. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:499-513.

Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. New Engl J Med. 2005;353:2135-2147.

Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.

El Ghissassi, Baan R, Straif K, et al. A review of human carcinogens – part D: Radiation. Lancet Oncol. 2009;10:751-752.

Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-703.

Freedman DM, Miller BA, Tucker MA. New Malignancies Following Melanoma of the Skin, Eye Melanoma, and Non-melanoma Eye Cancer. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at

Gangadhar TC, Fecher LA, Miller CJ, et al. Chapter 69: Melanoma. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD,, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012;87:991-1003.

Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012;62:30-67.

Leachman SA, Lowstuter K, Wadge LM. Genetic testing for melanoma. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:281-290.

National Cancer Institute. Physician Data Query (PDQ). Melanoma Treatment. 2016. Accessed at on March 9, 2016.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Melanoma. Version 2.2016. Accessed at on March 9, 2016.

Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: A meta-analysis of pigmentary characteristics and freckling. Int J Cancer. 2010;127:2430-2445.

Que SK, Fraga-Braghiroli N, Grant-Kels JM, et al. Through the looking glass: Basics and principles of reflectance confocal microscopy. J Am Acad Dermatol. 2015;73:276-284.

Ribas A, Slingluff CL, Rosenberg SA. Chapter 94: Cutaneous melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-924.

Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.

Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.